Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Fineline Cube May 18, 2026
Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Fineline Cube May 18, 2026
Company Drug

Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH

Fineline Cube Dec 9, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the presentation of preliminary Phase II...

Company Drug

Jacobio Pharma’s BET Inhibitor JAB-8263 Shows Promising Results in Myelofibrosis Phase I Study

Fineline Cube Dec 9, 2024

Jacobio Pharma (HKG: 1167) has announced the presentation of preliminary results from the Phase I...

Company Drug

Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026

Fineline Cube Dec 9, 2024

China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received clinical clearance from...

Company Drug

Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial

Fineline Cube Dec 8, 2024

Duality Biologics, in partnership with BioNTech (NASDAQ: BNTX), has announced the initial data from the...

Company Drug

Chipscreen Biosciences’ Chiauranib Phase III Trial Results for SCLC Announced

Fineline Cube Dec 8, 2024

China-based innovative drug company Chipscreen Biosciences (SHA: 688321) has announced the completion of the analysis...

Company Drug

Immunofoco’s IMC002 CAR-T Therapy Receives FDA Fast Track Designation for Gastric Cancer

Fineline Cube Dec 7, 2024

Immunofoco, a biotechnology company specializing in immunotherapy, has announced that its self-developed autologous CAR-T product,...

Company Drug

Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial

Fineline Cube Dec 7, 2024

Shanghai Juncell Therapeutics has announced that the National Medical Products Administration’s Center for Drug Evaluation...

Company Deals

AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics

Fineline Cube Dec 7, 2024

US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with...

Company Drug

Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials

Fineline Cube Dec 7, 2024

China-based cancer immunotherapy specialist Novatim Immune Therapeutics (Zhejiang) Co., Ltd. has announced receiving clinical clearance...

Policy / Regulatory

NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Dec 7, 2024

The National Medical Products Administration (NMPA) has released the 85th batch of reference drugs for...

Company Drug

HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors

Fineline Cube Dec 7, 2024

Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...

Company Drug

Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment

Fineline Cube Dec 6, 2024

The National Medical Products Administration (NMPA) of China has officially approved pretomanid, developed by Shenyang...

Company Deals

Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine

Fineline Cube Dec 6, 2024

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution...

Company Deals

GSK plc Partners with Muna Therapeutics to Discover Alzheimer’s Disease Treatment Targets

Fineline Cube Dec 6, 2024

GSK plc (NYSE: GSK) has announced a new partnership with Danish biotech firm Muna Therapeutics,...

Company Drug

Jiangsu Hengrui’s SHR-A2102 Earns Breakthrough Therapy Designation for Urothelial Carcinoma

Fineline Cube Dec 6, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received breakthrough therapy...

Company Drug

Roche’s Columvi Supplemental sBLA Accepted by FDA for Relapsed DLBCL Treatment

Fineline Cube Dec 6, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that the US Food and Drug Administration...

Company Drug

Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI

Fineline Cube Dec 6, 2024

Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings...

Company Deals

Eyebright Medical Technology Aims to Raise RMB 300 Million for Contact Lens Production Expansion

Fineline Cube Dec 6, 2024

China-based ophthalmic medical device manufacturer, Eyebright Medical Technology Co., Ltd (SHA: 688050), has announced plans...

Company Deals

Cambrex Partners with Eli Lilly to Enhance Clinical Development for Biotech Collaborators

Fineline Cube Dec 6, 2024

US-based contract development and manufacturing organization (CDMO) Cambrex has reached an agreement with Eli Lilly...

Company Deals Drug

Dewpoint Therapeutics Partners with Mitsubishi Tanabe Pharma to Develop ALS Treatment

Fineline Cube Dec 6, 2024

US-based Dewpoint Therapeutics Inc. has entered into a strategic partnership with Japan-headquartered Mitsubishi Tanabe Pharma...

Posts pagination

1 … 252 253 254 … 667

Recent updates

  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
  • AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data
  • Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction
  • Biogen’s Zorevunersen Receives China Breakthrough Therapy Designation for Dravet Syndrome – First ASO Targeting SCN1A Gene in Rare Epileptic Encephalopathy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Company Drug

AstraZeneca and Daiichi Sankyo’s ENHERTU Secures Dual FDA Approval for HER2-Positive Early Breast Cancer – Neoadjuvant and Adjuvant Indications Supported by Landmark Phase 3 Data

Company Drug

Roche’s Tecentriq Secures FDA Approval for ctDNA-Guided Adjuvant Treatment in Muscle-Invasive Bladder Cancer – First MRD-Directed Immunotherapy with 41% Mortality Reduction

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.